ID

30369

Descrizione

https://clinicaltrials.gov/ct2/show/NCT00486954 Study ID: 104578 Clinical Study ID: EGF104578 Study Title: A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination with weekly Paclitaxel versus weekly Paclitaxel alone in the second line treatment of ErbB2 amplified Advanced Gastric Cancer Patient Level Data: Clinicaltrials.gov Identifier: NCT00486954 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Product Sponsorship Transferred to Novartis Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Neoplasms, Gastrointestinal Tract CRF Seiten: 1288-1609

collegamento

https://clinicaltrials.gov/ct2/show/NCT00486954

Keywords

versioni (1)

1. 30/05/18 30/05/18 - Halim Ugurlu

Titolare del copyright

GlaxoSmithKline (GSK)

Caricato su

30 maggio 2018

DOI

Per favore, per richiedere un accesso.

Licenza